Alexza surges after inhaled antipsychotic drug gets support

Share this article:
Alexza surges after inhaled antipsychotic drug gets support
Alexza surges after inhaled antipsychotic drug gets support

Stock prices for Alexza Pharmaceuticals Inc. recently surged by 25% to 78 cents. This came after the Food and Drug Administration's  Psychopharmacologic Drugs Advisory Committee conditionally backed the drugmaker's plan to sell an inhaled antipsychotic drug. Adusave is approved for people with schizophrenia and bipolar mania. However, the panel's 9-8 vote was contingent on the company using a risk mitigation plan proposed by the FDA.

Share this article:

More in Products

Aviv REIT offers public stock

Aviv REIT announced the public offering of 8 million shares of common stock at a public offering price of $24.10 per share.

NCAL unveils 2014 Assisted Living Week logo

NCAL unveils 2014 Assisted Living Week logo

The National Center for Assisted Living is encouraging communities to use the 2014 "The Magic of Music" logo to celebrate National Assisted Living Week.

New healthcare educational catalog available

New healthcare educational catalog available

Nasco has released its 2014-2015 Health Care Educational Materials catalog, which focuses on training with versatile medical procedure simulators.